Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA approval and CE mark for Boston's new balloon catheter

This article was originally published in Clinica

Executive Summary

The US FDA has granted premarket approval (PMA) for Boston Scientific's NC Quantum Apex balloon catheter. The Natick, Massachusetts firm has also CE marked the product for sale in Europe, where it plans to launch it this week. US launch is slated to follow next month. The "next-generation" balloon catheter is designed for patients with coronary artery disease undergoing percutaneous coronary intervention, helping to optimise coronary stent deployment by opening arteries blocked by atherosclerosis. The catheter features a new Bi-Segment inner shaft for "improved trackability" and a re-designed tip for greater flexibility, Boston says. It is available in diameters of 2-5mm, and lengths of 6-30mm.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT094798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel